• Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

    Source: Nasdaq GlobeNewswire / 01 Sep 2023 08:00:00   America/New_York

    Fort Lee, NJ, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:

    Event H.C. Wainwright 25th Annual Global Investment Conference
    Date September 12, 2023
    Time 12:00 PM - 12:30 PM ET
    Location New York
    Webcast Link https://journey.ct.events/view/ac177925-4d81-4425-b349-9491973f53cb


    Event 2023 Cantor Global Healthcare Conference
    Date September 27, 2023
    Time 8:00 AM - 8:30 AM ET
    Location New York
    Webcast Link https://wsw.com/webcast/cantor19/nvct/2113419 

    About Nuvectis Pharma, Inc.

    Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule currently in a Phase 1b clinical trial investigating the activity of NXP800 as a potential treatment for platinum resistant, ARID1a-mutated ovarian carcinoma. The U.S. Food and Drug Administration (“FDA”) granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma. NXP900 is a novel, small molecule SRC/YES1 kinase inhibitor. The NXP900 Investigational New Drug Application has been cleared by the FDA and a Phase 1a dose escalation study is expected to begin in Q3 2023.

    Company Contact

    Ron Bentsur
    Chairman, Chief Executive Officer and President
    201-614-3151
    rbentsur@nuvectis.com

    Media Relations Contact

    Christopher M. Calabrese
    LifeSci Advisors
    Tel: 917-680-5608
    ccalabrese@lifesciadvisors.com 


    Primary Logo

Share on,